Note that some links may require subscriptions.
War on science? Not only does the Trump administration’s proposed 2020 budget slash funding for the National Institutes of Health, but also for NASA, NSF, NIST, and the research arms of cabinet departments including Energy and Agriculture. And don’t even ask about EPA. (Science, The Hill)
Smoking while pregnant may double a baby’s risk of sudden death. (CNN)
FiveThirtyEight, the statistics watchdog, blasted the CDC’s latest estimates of nonfatal gun injuries as probably too high and definitely too uncertain to be useful.
Another trastuzumab biosimilar approved, from Pfizer (the third after Celltrion’s and Mylan’s), to challenge brand-name Herceptin. (Reuters)
Head-to-head trial of vedolizumab (Entyvio) versus adalimumab (Humira) in ulcerative colitis favors the former, says its manufacturer, Takeda.
And in other drug news, Lilly said its ramucirumab (Cyramza) met its primary endpoint (progression-free survival) in a second phase III trial as first-line treatment for metastatic non-small cell lung cancer with activating EGFR mutations.
Moderate muscle strength from resistance exercise may substantially lower type 2 diabetes risk. (Medical News Today)
Eye exams may be useful in detecting Alzheimer’s disease. (ABC 11)
A rodent study highlights a molecular mechanism possibly connecting adolescent alcohol use with adult anxiety. (NIH)
Parents consider vaping around their children to be safe. (Today)
Breast cancer researchers are setting out to treat their patients in less invasive ways that skip surgery altogether. (The Wall Street Journal)
During emergency room visits, screening results show many preteens are positive for suicide risk. (NIH)
Police shot a gunman outside the Hacienda HealthCare facility in Phoenix where an incapacitated woman gave birth last year, although the incidents appear unrelated. (NBC News)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]